UP!

ADXS $0.37   View long term graphs

Advaxis, Inc.
Type
Public
Traded as NASDAQ: ADXS
Industry Biotechnology
Healthcare
Predecessor Great Expectations, Inc.
Founded United States (March 1, 2002 (2002-03-01))
Headquarters Princeton, New Jersey, United States
Key people
  • Daniel O'Connor (CEO)
  • Dr. Robert Petit
  • Yvonne Paterson
Products Immunotherapies for cancer
Website www.advaxis.com

Advaxis is an American company devoted to the discovery, development and commercialization of immunotherapies based on a technology platform which uses engineered Listeria monocytogenes (aka Lm). The company is headquartered in Princeton, New Jersey and was incorporated in Delaware in 2006.

The Lm-based platform on which the company's products are based involves the use of attenuated Lm which secrete antigen/adjuvant fusion proteins and stimulate a patient's immune system (specifically their T cells) to mount an immune response to the secreted antigen; if the antigen is specifically found on cancerous cells, then the result aims to be an effective immune response targeting and eliminating the cancer. Treatments developed using this paradigm are referred to as Lm-LLO immunotherapies.

Today, the Company has over fifteen distinct constructs in various stages of development, directly developed by the Company and through strategic collaborations with recognized centers of excellence such as: the National Cancer Institute, Cancer Research – UK, the Wistar Institute, the University of Pennsylvania, and the Department of Homeland Security among others.

The Company also has a veterinary medicine program that is evaluating an Lm-LLO based immunotherapy in a Phase 1 study in canine osteosarcoma. Source: www.advaxis.com

Advaxis was a Delaware corporation when it was acquired by a shell corporation (in the official SEC sense) in November 2004. The acquiring company was Great Expectations, which was incorporated in Colorado in June 1987. The only operating company owned by Great Expectations was Advaxis and in 2004, a month after the acquisition, it changed its name to Advaxis, and 18 months after that it reincorporated as a Delaware corporation. The official 'date of inception' for the company is 1 March 2002.

As of December 2013, the COO of Advaxis was Gregory Mayes.

In 2014, Advaxis entered a co-development and commercialization agreement with India's Biocon for the ADXS-HPV therapeutic in the Indian market, addressing HPV-associated cancers, including cervical cancer.

Advaxis immunotherapies are based on a novel platform technology using live attenuated Listeria monocytogenes (Lm) that are bio-engineered to secrete an antigen/adjuvant fusion protein. The vectors infect the key elements of the immune system and the secreted antigen/adjuvant fusion protein redirects the powerful immune response all human beings inherit to Lm against the cancer, itself. The adjuvant also reduces the cancer’s defense against this immune attack by 80%.

ADXS-HPV is in Phase 2 trials for HPV-associated diseases (cervical intraepithelial neoplasia (CIN), cervical cancer and HPV-associated head and neck cancer).

In 2009 Advaxis published the results of the first Phase 1 trial with the first Lm-LLO based immunotherapy, ADXS-HPV in Vaccine (19 June 2009 / Volume 27, Issue 30). This study assessed side effects associated with increasing doses of ADXS-HPV in patients with metastatic, refractory, recurrent cervical cancer. Vaccine (19 June 2009 / Volume 27, Issue 30)

Advaxis’ intellectual property includes over 70 pending and issued patents. On May 18, 2010, Advaxis and the University of Pennsylvania signed an agreement granting Advaxis exclusive rights to 27 remaining patents held by the University of Pennsylvania.

Q reports

Period Date Adjusted Actuals EPS GAAP EPS
Q4 2020 2020-12-18 Future report Set alerts
Q3 2020 2020-09-07 0.00 0.00
Q2 2020 2020-06-11 -0.10 -0.10
Q1 2020 2020-03-13 -0.15 -0.15
Q4 2019 2019-12-20 -0.15 -0.25
Q3 2019 2019-09-09 -0.96 -1.00
Q2 2019 2019-06-10 -1.32 -1.59
Q1 2019 2019-03-12 -0.89 2.70
Q4 2018 2019-01-10 -4.35 -4.35
Q3 2018 2018-09-10 -4.05 -4.05

Ratings

2016-07-07 Reiterated Rating FBR & Co Outperform $34.00
2016-06-29 Reiterated Rating HC Wainwright Buy
2016-06-10 Reiterated Rating Jefferies Group Buy
2016-06-09 Reiterated Rating HC Wainwright Buy $23.00
2016-05-17 Reiterated Rating FBR & Co. Outperform $34.00
2016-05-17 Reiterated Rating FBR & Co Outperform $34.00
2016-04-21 Reiterated Rating HC Wainwright Buy
2016-03-29 Reiterated Rating FBR & Co. Outperform to Positive $34.00
2016-03-09 Reiterated Rating FBR & Co. Outperform
2016-03-07 Reiterated Rating HC Wainwright Buy $23.00
2016-02-24 Lower Price Target Barclays Overweight $30.00 to $15.00
2016-02-24 Lower Price Target Barclays PLC Overweight $30.00 to $15.00
2016-02-07 Reiterated Rating HC Wainwright Buy $30.00
2015-12-23 Reiterated Rating HC Wainwright Buy $30.00
2015-12-17 Reiterated Rating Janney Montgomery Scott Buy $22.00
2015-12-16 Reiterated Rating FBR & Co. Buy $34.00
2015-10-30 Reiterated Rating FBR & Co. Outperform
2015-10-09 Reiterated Rating HC Wainwright Buy $30.00
2015-10-08 Reiterated Rating FBR & Co. Outperform $34.00
2015-09-22 Initiated Coverage Barclays Overweight $40.00
2015-09-18 Reiterated Rating HC Wainwright Buy $30.00
2015-09-14 Reiterated Rating FBR & Co. Positive
2015-09-11 Initiated Coverage Guggenheim Buy $30.00
2015-06-26 Initiated Coverage MLV & Co. Buy
2015-06-26 Initiated Coverage HC Wainwright Buy
2015-06-20 Set Price Target MLV & Co. Buy $34.00
2015-06-16 Boost Price Target HC Wainwright Buy $25.00 to $30.00
2015-05-15 Initiated Coverage Jefferies Group Buy $27.00
2015-05-14 Initiated Coverage Janney Montgomery Scott Buy $26.00
2015-05-14 Initiated Coverage MLV & Co. Buy $34.00
2015-03-17 Reiterated Rating Noble Financial Buy
2015-01-08 Reiterated Rating Aegis Buy to Positive
2014-12-30 Reiterated Rating Aegis Buy
2014-12-15 Reiterated Rating Aegis Buy
2014-10-23 Initiated H.C. Wainwright Buy $8
2014-10-23 Initiated Coverage HC Wainwright Buy $8.00
2014-02-18 Initiated Aegis Capital Buy $18
2014-02-18 Initiated Coverage Aegis Buy $18.00
2014-02-10 Initiated Coverage Noble Financial Buy $12.00
2016-07-07 Reiterated Rating FBR & Co Outperform $34.00
2016-06-29 Reiterated Rating HC Wainwright Buy
2016-06-10 Reiterated Rating Jefferies Group Buy
2016-06-09 Reiterated Rating HC Wainwright Buy $23.00
2016-05-17 Reiterated Rating FBR & Co. Outperform $34.00

There is presents forecasts of rating agencies and recommendations for investors about this ticker

Funds

In ADXS 0 funds of 2186 total. Show all

Fund name Ticker shares

Major Shareholders

Name Relationship Total Shares Holding stocks
ADAGE CAPITAL PARTNERS GP LLC 21.01%  (4100043) ADXS / AMAG / BDBD / CALA / FPRX / HTWR / IGOI / PBYI / PSUN / PTGX /
O'Connor Daniel SVP, Legal & Business Dev Off 3.17%  (618352) ADXS / ONCS /
Berlin Kenneth A President & CEO 1.28%  (250000) ADXS /
Bonstein Sara Chief Financial Officer 1.16%  (226670) ADXS /
PETIT ROBERT Chief Scientific Officer 1.15%  (224874) ADXS /
PATTON JAMES P 1.08%  (211749) ADXS /
MOORE THOMAS A CHAIRMAN / CEO 0.90%  (176462) ADXS /
Mauro David J Chief Medical Officer 0.85%  (166271) ADXS /
APPEL RONI 0.63%  (123810) ADXS /
Rosenblum Mark J CFO, Senior VP & Secretary 0.58%  (113774) ADXS /
Mayes, Gregory T. Chief Operating Officer 0.53%  (103841) ADXS / ONCS /
LOMBARDO ANTHONY A Interim CEO 0.42%  (81852) ADXS /
SIDRANSKY DAVID 0.41%  (80355) ADXS / CSBR / IMNP /
FRENCH CHRISTY LEE Exec. Dir. of Medical Affairs 0.37%  (71938) ADXS /
MCKEARN THOMAS J 0.36%  (69804) ADXS / ONTX /
Khleif Samir N 0.36%  (69587) ADXS /
BERMAN RICHARD J 0.26%  (50669) ADXS / APRI / NBS /
Ridge Thomas J 0.12%  (24306) ADXS / EXC / HSY / LOCK /

Comments